Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PDCD1LG2 | Q9BQ51 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23725488 | 0.88 | KCNA5 (0.41) | KCNA5LMNAMAPTMEN1POLB | |
| SCHEMBL23726417 | 0.85 | IRAK4 (0.35) | POLBCD274PDCD1MAPK1PDCD1LG2 | |
| SCHEMBL23724673 | 0.78 | CD274 (0.47) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL27080503 | 0.78 | CD274 (0.47) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL27036518 | 0.74 | CD274 (0.40) | KCNA5CD274PDCD1MAPK1PDCD1LG2 | |
| SCHEMBL27147971 | 0.74 | CD274 (0.40) | KCNA5CD274PDCD1MAPK1PDCD1LG2 | |
| SCHEMBL28903083 | 0.74 | CD274 (0.39) | KCNA5MEN1POLBKMT2ACD274 | |
| SCHEMBL23726706 | 0.74 | CD274 (0.56) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL23724890 | 0.74 | CD274 (0.57) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL25175600 | 0.74 | CD274 (0.57) | CD274PDCD1PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4100381-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158481-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | KCNA5 3984/4885LMNA 2184/4885MAPT 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.